Skip to main content
Clinical Trials/IRCT20180417039347N1
IRCT20180417039347N1
Recruiting
Phase 3

Prophylactic effect of N-acetyl-cysteine plus Atorvastatin versus N-acetyl-cysteine and Atorvastatin alone for the prevention of contrast induced nephropathy in patients undergoing elective angiography with or without percutaneous coronary intervention: a single center prospective randomized controlled trial

Zahedan University of Medical Sciences0 sites250 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Contrast induced nephropathy.
Sponsor
Zahedan University of Medical Sciences
Enrollment
250
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Zahedan University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Eligible patients include individuals older than 21 years old
  • abnormal renal function (Creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) \=1\.1 mg/dL)
  • Undergoing elective cardiac catheterization with or without PCI

Exclusion Criteria

  • Patients with end\-stage renal failure (glomerular filtration rate (GFR) \= 15 mL/min),
  • history of previous dialysis
  • pulmonary edema
  • emergency cardiac catheterization (patients with ST\-segment elevation myocardial infarction undergoing primary PCI ),
  • exposure to contrast within previous two days ago before procedure
  • allergies to contrast media,
  • contraindication to statins
  • liver disease

Outcomes

Primary Outcomes

Not specified

Similar Trials